Literature DB >> 26267440

Lung Cancer Resection at Hospitals With High vs Low Mortality Rates.

Tyler R Grenda1, Sha'Shonda L Revels1, Huiying Yin1, John D Birkmeyer2, Sandra L Wong1.   

Abstract

IMPORTANCE: Wide variations in mortality rates exist across hospitals following lung cancer resection; however, the factors underlying these differences remain unclear.
OBJECTIVE: To evaluate perioperative outcomes in patients who underwent lung cancer resection at hospitals with very high and very low mortality rates (high-mortality hospitals [HMHs] and low-mortality hospitals [LMHs]) to better understand the factors related to differences in mortality rates after lung cancer resection. DESIGN, SETTING, AND PARTICIPANTS: In this retrospective cohort study, 1279 hospitals that were accredited by the Commission on Cancer were ranked on a composite measure of risk-adjusted mortality following major cancer resections performed from January 1, 2005, through December 31, 2006. We collected data from January 1, 2006, through December 31, 2007, on 645 lung resections in 18 LMHs and 25 HMHs. After adjusting for patient characteristics, we used hierarchical logistic regression to examine differences in the incidence of complications and "failure-to-rescue" rates (defined as death following a complication). MAIN OUTCOMES AND MEASURES: Rates of adherence to processes of care, incidence of complications, and failure to rescue following complications.
RESULTS: Among 645 patients who received lung resections (441 in LMHs and 204 in HMHs), the overall unadjusted mortality rates were 1.6% (n = 7) vs 10.8% (n = 22; P < .001) for LMHs and HMHs, respectively. Following risk adjustment, the difference in mortality rates was attenuated (1.8% vs 8.1%; P < .001) but remained significant. Overall, complication rates were higher in HMHs (23.3% vs 15.6%; adjusted odds ratio [aOR], 1.79; 95% CI, 0.99-3.21), but this difference was not significant. The likelihood of any surgical (aOR, 0.73; 95% CI, 0.26-2.00) or cardiopulmonary (aOR, 1.23; 95% CI, 0.70-2.16) complications was similar between LMHs and HMHs. However, failure-to-rescue rates were significantly higher in HMHs (25.9% vs 8.7%; aOR, 6.55; 95% CI, 1.44-29.88). CONCLUSIONS AND RELEVANCE: Failure-to-rescue rates are higher at HMHs, which may explain the large differences between hospitals in mortality rates following lung cancer resection. This finding emphasizes the need for better understanding of the factors related to complications and their subsequent management.

Entities:  

Mesh:

Year:  2015        PMID: 26267440      PMCID: PMC5098553          DOI: 10.1001/jamasurg.2015.2199

Source DB:  PubMed          Journal:  JAMA Surg        ISSN: 2168-6254            Impact factor:   14.766


  18 in total

1.  Trends in hospital volume and operative mortality for high-risk surgery.

Authors:  Jonathan F Finks; Nicholas H Osborne; John D Birkmeyer
Journal:  N Engl J Med       Date:  2011-06-02       Impact factor: 91.245

2.  Reliability adjustment for reporting hospital outcomes with surgery.

Authors:  Justin B Dimick; Amir A Ghaferi; Nicholas H Osborne; Clifford Y Ko; Bruce L Hall
Journal:  Ann Surg       Date:  2012-04       Impact factor: 12.969

3.  Empirically derived composite measures of surgical performance.

Authors:  Douglas O Staiger; Justin B Dimick; Onur Baser; Zhaohui Fan; John D Birkmeyer
Journal:  Med Care       Date:  2009-02       Impact factor: 2.983

4.  Failure to rescue as a source of variation in hospital mortality after hepatic surgery.

Authors:  G Spolverato; A Ejaz; O Hyder; Y Kim; T M Pawlik
Journal:  Br J Surg       Date:  2014-04-23       Impact factor: 6.939

5.  Comorbidity measures for use with administrative data.

Authors:  A Elixhauser; C Steiner; D R Harris; R M Coffey
Journal:  Med Care       Date:  1998-01       Impact factor: 2.983

6.  The Society of Thoracic Surgeons General Thoracic Surgery Database: establishing generalizability to national lung cancer resection outcomes.

Authors:  Damien J LaPar; Castigliano M Bhamidipati; Christine L Lau; David R Jones; Benjamin D Kozower
Journal:  Ann Thorac Surg       Date:  2012-05-18       Impact factor: 4.330

7.  Hospital characteristics associated with failure to rescue from complications after pancreatectomy.

Authors:  Amir A Ghaferi; Nicholas H Osborne; John D Birkmeyer; Justin B Dimick
Journal:  J Am Coll Surg       Date:  2010-07-14       Impact factor: 6.113

8.  Impact of hospital volume on operative mortality for major cancer surgery.

Authors:  C B Begg; L D Cramer; W J Hoskins; M F Brennan
Journal:  JAMA       Date:  1998-11-25       Impact factor: 56.272

9.  Variation in hospital mortality rates with inpatient cancer surgery.

Authors:  Sandra L Wong; ShaʼShonda L Revels; Huiying Yin; Andrew K Stewart; Andrea McVeigh; Mousumi Banerjee; John D Birkmeyer
Journal:  Ann Surg       Date:  2015-04       Impact factor: 12.969

10.  Monitoring the delivery of cancer care: Commission on Cancer and National Cancer Data Base.

Authors:  Richelle T Williams; Andrew K Stewart; David P Winchester
Journal:  Surg Oncol Clin N Am       Date:  2012-04-17       Impact factor: 3.495

View more
  4 in total

1.  Risk-Adjusted Margin Positivity Rate as a Surgical Quality Metric for Non-Small Cell Lung Cancer.

Authors:  Chun Chieh Lin; Matthew P Smeltzer; Ahmedin Jemal; Raymond U Osarogiagbon
Journal:  Ann Thorac Surg       Date:  2017-07-12       Impact factor: 4.330

2.  Prognostic Value of National Comprehensive Cancer Network Lung Cancer Resection Quality Criteria.

Authors:  Raymond U Osarogiagbon; Meredith A Ray; Nicholas R Faris; Matthew P Smeltzer; Carrie Fehnel; Cheryl Houston-Harris; Raymond S Signore; Laura M McHugh; Paul Levy; Lynn Wiggins; Vishal Sachdev; Edward T Robbins
Journal:  Ann Thorac Surg       Date:  2017-03-31       Impact factor: 4.330

3.  Colon cancer operations at high- and low-mortality hospitals.

Authors:  Mark A Healy; Tyler R Grenda; Pasithorn A Suwanabol; Huiying Yin; Amir A Ghaferi; John D Birkmeyer; Sandra L Wong
Journal:  Surgery       Date:  2016-06-14       Impact factor: 3.982

4.  Knockdown of SALL4 inhibits the proliferation, migration, and invasion of human lung cancer cells in vivo and in vitro.

Authors:  Jiaping Li; Yan Zhang; Xinlu Tao; Qi You; Zheng Tao; Yan Zhang; Zhijie He; Jun Ou
Journal:  Ann Transl Med       Date:  2020-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.